Innovative Advances in Chronic Back Pain Treatment
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is making significant strides in the realm of regenerative medicine, particularly with its revolutionary therapy, CELZ-201. Recently, the company announced a major milestone in its clinical trial efforts with the successful completion of an independent interim safety review by the Data Safety Monitoring Board (DSMB). This review marks an important step in the ADAPT clinical trial, which targets chronic lower back pain associated with degenerative disc disease.
Positive Outcomes from the Interim Safety Review
The DSMB's assessment focused on safety data from the first five patients who received the treatment. Their conclusion that the trial may proceed as originally planned underscores the robust safety profile of CELZ-201. This interim review is built on a comprehensive 30-day dose-limiting toxicity (DLT) assessment, which is a crucial aspect as the trial progresses towards potentially groundbreaking therapeutic outcomes. The encouraging feedback from the DSMB not only validates the therapy but also enhances the overall confidence of the research team.
Insights from Leadership on CELZ-201's Potential
Timothy Warbington, the CEO of Creative Medical Technology Holdings, expressed his enthusiasm for the positive review, stating, "This validation fuels our confidence in the safety and viability of our regenerative biologic approach." His insights highlight the commitment of the team and the immense potential of CELZ-201 to address a condition that affects 16 million individuals across the nation, many of whom face limited long-term solutions.
Details of the ADAPT Trial Design
The ADAPT trial, known by its formal designation CELZ-201-ADAPT-2023, is structured as a double-blind, randomized, placebo-controlled, and dose-escalation study. It aims to thoroughly assess the safety, tolerability, and efficacy of CELZ-201, which is administered intramuscularly using advanced ultrasound techniques for efficacy. Given that patient safety is paramount, the trial employs strict protocol-driven monitoring of adverse events, following the Common Terminology Criteria for Adverse Events (CTCAE v.5). Regular reviews by the DSMB will continue to ensure compliance with safety standards as the trial progresses.
Creative Medical Technology's Broader Mission
Beyond CELZ-201, Creative Medical Technology Holdings is dedicated to exploring and developing innovative therapies within the regenerative medicine sector. The company is focused on providing effective treatments for conditions that currently lack adequate solutions, thereby fulfilling its mission to address high-need medical issues. Their commitment to combining rigorous scientific principles with strategic insights is making a noticeable impact in the field.
Dedication to Transformative Care
As a clinical-stage biotechnology company, Creative Medical Technology Holdings, Inc. is pioneering its path in regenerative medicine. Through extensive research and development efforts, the company aims to deliver transformative treatments derived from adult stem cell technologies. Their focus remains firmly on translating scientific advancements into real-world, accessible healthcare solutions for patients.
Contact Information
For more information about Creative Medical Technology Holdings, please contact:
Creative Medical Technology
IR@CreativeMedicalTechnology.com
Frequently Asked Questions
What is the ADAPT clinical trial?
The ADAPT trial is a clinical study evaluating the safety and efficacy of CELZ-201, a novel treatment for chronic lower back pain.
What does DSMB stand for and what is its role?
The Data Safety Monitoring Board (DSMB) reviews trial data to ensure patient safety and assess potential risks.
What is CELZ-201?
CELZ-201 is a regenerative therapy derived from perinatal tissue designed to treat chronic lower back pain.
How many patients were evaluated in the interim safety review?
Five patients who received the treatment were included in the evaluation conducted by the DSMB.
What is the significance of the positive DSMB review?
The positive review indicates that the trial can continue as planned, reinforcing the safety profile of CELZ-201 and its potential for therapeutic use.
